170 related articles for article (PubMed ID: 32750526)
21. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
[TBL] [Abstract][Full Text] [Related]
22. The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator.
Lin H; Shi F; Gao J; Hua P
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31341010
[TBL] [Abstract][Full Text] [Related]
23. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.
Williams E; Bullock AN
Bone; 2018 Apr; 109():251-258. PubMed ID: 28918311
[TBL] [Abstract][Full Text] [Related]
24. Development of an ALK2-biased BMP type I receptor kinase inhibitor.
Mohedas AH; Xing X; Armstrong KA; Bullock AN; Cuny GD; Yu PB
ACS Chem Biol; 2013; 8(6):1291-302. PubMed ID: 23547776
[TBL] [Abstract][Full Text] [Related]
25. Recent Advances in ALK2 Inhibitors.
Rooney L; Jones C
ACS Omega; 2021 Aug; 6(32):20729-20734. PubMed ID: 34423181
[TBL] [Abstract][Full Text] [Related]
26. Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2.
Fujimoto M; Ohte S; Shin M; Yoneyama K; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Machiya A; Okuda A; Suda N; Katagiri T
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):347-52. PubMed ID: 25446088
[TBL] [Abstract][Full Text] [Related]
27. Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases.
Han HJ; Jain P; Resnick AC
Bone; 2018 Apr; 109():91-100. PubMed ID: 28780023
[TBL] [Abstract][Full Text] [Related]
28. A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor.
Fukuda T; Kanomata K; Nojima J; Kokabu S; Akita M; Ikebuchi K; Jimi E; Komori T; Maruki Y; Matsuoka M; Miyazono K; Nakayama K; Nanba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Haga N; Furuya H; Katagiri T
Biochem Biophys Res Commun; 2008 Dec; 377(3):905-9. PubMed ID: 18952055
[TBL] [Abstract][Full Text] [Related]
29. Bone morphogenetic protein receptors: Structure, function and targeting by selective small molecule kinase inhibitors.
Sanchez-Duffhues G; Williams E; Goumans MJ; Heldin CH; Ten Dijke P
Bone; 2020 Sep; 138():115472. PubMed ID: 32522605
[TBL] [Abstract][Full Text] [Related]
30. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.
Chaikuad A; Alfano I; Kerr G; Sanvitale CE; Boergermann JH; Triffitt JT; von Delft F; Knapp S; Knaus P; Bullock AN
J Biol Chem; 2012 Oct; 287(44):36990-8. PubMed ID: 22977237
[TBL] [Abstract][Full Text] [Related]
31. Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva.
Takahashi M; Katagiri T; Furuya H; Hohjoh H
Gene Ther; 2012 Jul; 19(7):781-5. PubMed ID: 22130450
[TBL] [Abstract][Full Text] [Related]
32. Activation of G
Ebner JK; König GM; Kostenis E; Siegert P; Aktories K; Orth JHC
Bone; 2019 Oct; 127():592-601. PubMed ID: 31376533
[TBL] [Abstract][Full Text] [Related]
33. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.
Culbert AL; Chakkalakal SA; Theosmy EG; Brennan TA; Kaplan FS; Shore EM
Stem Cells; 2014 May; 32(5):1289-300. PubMed ID: 24449086
[TBL] [Abstract][Full Text] [Related]
34. ACVR1 mutations in DIPG: lessons learned from FOP.
Taylor KR; Vinci M; Bullock AN; Jones C
Cancer Res; 2014 Sep; 74(17):4565-70. PubMed ID: 25136070
[TBL] [Abstract][Full Text] [Related]
35. Fibrodysplasia ossificans progressiva-related activated activin-like kinase signaling enhances osteoclast formation during heterotopic ossification in muscle tissues.
Yano M; Kawao N; Okumoto K; Tamura Y; Okada K; Kaji H
J Biol Chem; 2014 Jun; 289(24):16966-77. PubMed ID: 24798338
[TBL] [Abstract][Full Text] [Related]
36. Recent progress in drug development for fibrodysplasia ossificans progressiva.
Meng X; Wang H; Hao J
Mol Cell Biochem; 2022 Oct; 477(10):2327-2334. PubMed ID: 35536530
[TBL] [Abstract][Full Text] [Related]
37. Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva.
Kaplan FS; Seemann P; Haupt J; Xu M; Lounev VY; Mullins M; Shore EM
Methods Enzymol; 2010; 484():357-73. PubMed ID: 21036241
[TBL] [Abstract][Full Text] [Related]
38. Fibrodysplasia ossificans progressiva.
Kaplan FS; Le Merrer M; Glaser DL; Pignolo RJ; Goldsby RE; Kitterman JA; Groppe J; Shore EM
Best Pract Res Clin Rheumatol; 2008 Mar; 22(1):191-205. PubMed ID: 18328989
[TBL] [Abstract][Full Text] [Related]
39. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice.
Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H
J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847
[TBL] [Abstract][Full Text] [Related]
40. [Cytokines in bone diseases. BMP signaling and fibrodysplasia ossificans progressiva].
Katagiri T; Kamizono J; Nakashima Y; Kitoh H; Susami T; Haga N
Clin Calcium; 2010 Oct; 20(10):1510-7. PubMed ID: 20890033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
